Off-label adjunctive use requires careful dosing, dose adjustments of insulin and other medications, and close monitoring.

The FDA has approved a higher dose version of the GLP-1 drug Wegovy, which could lead to greater weight loss. The new dose is ...

By now you've heard plenty of buzz about GLP-1 medications like Ozempic, Wegovy and Zepbound. Originally developed for type 2 ...

The FDA granted approval for the GLP-1 dosage in just 54 days. The Wegovy pill, rather than injections, was approved in ...

(NEXSTAR) – The World Health Organization has issued new guidance on the use of popular GLP-1 drugs, like Ozempic, Wegovy, Mounjaro, and Zepbound, to treat the “major global health challenge” of ...

In a small new study, most people who switched from weekly to every-other-week GLP-1 dosing maintained their weight loss and metabolic health improvements. A fraction of the people regained weight and ...

ATLANTA -- Patients with plateaued weight loss or who reached their weight-related goals on a GLP-1 receptor agonist were able to maintain their improvements in weight, body composition, and metabolic ...

The WHO issued new guidelines endorsing GLP-1 receptor agonists for the long-term treatment of obesity in adults. GLP-1 drugs must be combined with counseling on behavioral and lifestyle changes, the ...

Doctors explain the differences between the Wegovy pill and injection in terms of efficacy, side effects, and more. They ...

In a first, the World Health Organization has issued a guideline on GLP-1s, a drug class that up to 1 in 8 U.S. adults report using, according to KFF research. The WHO’s guideline, published Dec. 1 in ...

Ascletis Pharma has posted phase 2 data on its ultra-long-acting GLP-1 receptor analog, generating early evidence that the formulation may support quarterly dosing as a maintenance therapy. Eli ...

MedImpact has announced the launch of GLP-1 Benefit 360 and GLP-1 Direct Fund, aimed at addressing inefficiencies in the drug ...